NEW YORK, Aug. 18, 2004 (PRIMEZONE) -- Home Solutions Health, Inc. (Pink Sheets:HSHL) announced today that July sales of its Hemorrelief increased over 400% compared with June sales. The sales increase is directly attributable to the Company's media campaign on The Howard Stern Show. The Company has extended its advertising efforts with The Howard Stern Show through October. It is estimated that The Howard Stern Show has an estimated 18 million daily listeners. The Company will be introducing other media campaigns through the balance of the third and fourth quarters. The Company anticipates that these advertising and marketing efforts will continue to drive sales of its Hemorrelief product significantly in the months ahead.
"We are pleased with results of our advertising efforts with The Howard Stern Show. We expect that our future advertising efforts will have similar results," comments Home Solutions Health CEO Steven Bingaman.
Hemorrelief is an effective, patented, FDA approved, low-cost treatment for the burning, itching and severe pain associated with hemorrhoids. Hemorrelief is a cooling devise that reduces swelling for more than 90% of all hemorrhoid sufferers who use the product. Hemorrelief contains no chemicals or medications and requires no special prescription. Treatment can take as little as 10 minutes a day. Hemorrelief is low-cost re-useable, easy to use, and far more economical than any other hemorrhoid treatment. In many cases, hemorrhoids treated with Hemorrelief improve to the point where painful surgery and other invasive treatments are completely unnecessary. Hemorrelief can be purchased by calling 1 888 HEM KOOL or at www.hemorrelief.com
Home Solutions Health, Inc. is traded under the symbol HSHL on the pink sheets. Any forward-looking statements in this report are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence upon third party suppliers, intellectual property rights and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.